A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy

被引：83

作者：

Zhang, Lianhai ^{[1
]}

Yang, Jie ^{[3
]}

Cai, Jie ^{[3
]}

Song, Xiaoming ^{[3
]}

Deng, Jianyun ^{[3
]}

Huang, Xuesong ^{[3
]}

Chen, Dawei ^{[3
]}

Yang, Mengmeng ^{[3
]}

Wery, Jean-Pierre ^{[3
]}

Li, Shuangxi ^{[1
]}

Wu, Aiwen ^{[1
]}

Li, Ziyu ^{[1
]}

Li, Zhongwu ^{[2
]}

Liu, Yiqiang ^{[2
]}

Chen, Yiyou ^{[3
]}

Li, Qixiang ^{[3
,4
]}

Ji, Jiafu ^{[1
]}

机构：

[1] Peking Univ, Canc Hosp & Inst, Dept Surg, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China

[2] Peking Univ, Canc Hosp & Inst, Dept Pathol, Beijing 100871, Peoples R China

[3] Crown Biosci Inc Beijing, Beijing, Peoples R China

[4] Peking Univ, State Key Lab Nat & Biomimet Drugs, Beijing 100871, Peoples R China

来源：

SCIENTIFIC REPORTS | 2013年 / 3卷

关键词：

PHASE-II; PLUS OXALIPLATIN/LEUCOVORIN/5-FLUOROURACIL; BIOMARKER ANALYSIS; XENOGRAFTS; ESTABLISHMENT; PANEL; KRAS; BRAF;

D O I：

10.1038/srep02992

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.

引用

页数：6

共 21 条

[1]

Bang YJ, 2010, LANCET, V376, P1302

[2] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].

Bonner, James A. ;

Harari, Paul M. ;

Giralt, Jordi ;

Cohen, Roger B. ;

Jones, Christopher U. ;

Sur, Ranjan K. ;

Raben, David ;

Baselga, Jose ;

Spencer, Sharon A. ;

Zhu, Junming ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Ang, K. Kian .

LANCET ONCOLOGY, 2010, 11 (01) :21-28

[3] KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer [J].

De Roock, Wendy ;

De Vriendt, Veerle ;

Normanno, Nicola ;

Ciardiello, Fortunato ;

Tejpar, Sabine .

LANCET ONCOLOGY, 2011, 12 (06) :594-603

[4] Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis [J].

De Roock, Wendy ;

Claes, Bart ;

Bernasconi, David ;

De Schutter, Jef ;

Biesmans, Bart ;

Fountzilas, George ;

Kalogeras, Konstantine T. ;

Kotoula, Vassiliki ;

Papamichael, Demetris ;

Laurent-Puig, Pierre ;

Penault-Llorca, Frederique ;

Rougier, Philippe ;

Vincenzi, Bruno ;

Santini, Daniele ;

Tonini, Giuseppe ;

Cappuzzo, Federico ;

Frattini, Milo ;

Molinari, Francesca ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Martini, Miriam ;

Bardelli, Alberto ;

Siena, Salvatore ;

Sartore-Bianchi, Andrea ;

Tabernero, Josep ;

Macarulla, Teresa ;

Di Fiore, Frederic ;

Gangloff, Alice Oden ;

Ciardiello, Fortunato ;

Pfeiffer, Per ;

Qvortrup, Camilla ;

Hansen, Tine Plato ;

Van Cutsem, Eric ;

Piessevaux, Hubert ;

Lambrechts, Diether ;

Delorenzi, Mauro ;

Tejpar, Sabine .

LANCET ONCOLOGY, 2010, 11 (08) :753-762

[5] Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].

Di Nicolantonio, Federica ;

Martini, Miriam ;

Molinari, Francesca ;

Sartore-Bianchi, Andrea ;

Arena, Sabrina ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Mazzucchelli, Luca ;

Frattini, Milo ;

Siena, Salvatore ;

Bardelli, Alberto .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712

[6] Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers [J].

Fichtner, Iduna ;

Rolff, Jana ;

Soong, Richie ;

Hoffmann, Jens ;

Hammer, Stefanie ;

Sommer, Anette ;

Becker, Michael ;

Merk, Johannes .

CLINICAL CANCER RESEARCH, 2008, 14 (20) :6456-6468

[7] Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer [J].

Han, S-W ;

Oh, D-Y ;

Im, S-A ;

Park, S. R. ;

Lee, K-W ;

Song, H. S. ;

Lee, N-S ;

Lee, K. H. ;

Choi, I. S. ;

Lee, M. H. ;

Kim, M. A. ;

Kim, W. H. ;

Bang, Y-J ;

Kim, T-Y .

BRITISH JOURNAL OF CANCER, 2009, 100 (02) :298-304

[8] Promoter Methylation in Head and Neck Squamous Cell Carcinoma Cell Lines Is Significantly Different than Methylation in Primary Tumors and Xenografts [J].

Hennessey, Patrick T. ;

Ochs, Michael F. ;

Mydlarz, Wojciech W. ;

Hsueh, Wayne ;

Cope, Leslie ;

Yu, Wayne ;

Califano, Joseph A. .

PLOS ONE, 2011, 6 (05)

[9] A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer [J].

Kim, Chul ;

Lee, Jae-Lyun ;

Ryu, Min-Hee ;

Chang, Heung Moon ;

Kim, Tae Won ;

Lim, Ho Young ;

Kang, Hye Jin ;

Park, Young Suk ;

Ryoo, Baek-Yeol ;

Kang, Yoon-Koo .

INVESTIGATIONAL NEW DRUGS, 2011, 29 (02) :366-373

[10] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J].

Lièvre, A ;

Bachet, JB ;

Le Corre, D ;

Boige, V ;

Landi, B ;

Emile, JF ;

Côté, JF ;

Tomasic, G ;

Penna, C ;

Ducreux, M ;

Rougier, P ;

Penault-Llorca, F ;

Laurent-Puig, P .

CANCER RESEARCH, 2006, 66 (08) :3992-3995

← 1 2 3 →